

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

**Claims 1-47 (Canceled)**

**Claim 48 (Previously presented)** A method of enhancing wound healing in a patient, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 49 (Previously presented)** The method of claim 48, wherein the wound healing is selected from the group consisting of burns, surgical incisions, lacerations, ulcers, and traumas.

**Claim 50 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 51 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Asp101~~ [Asp<sup>101</sup>].

**Claim 52 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Leu137~~ [Leu<sup>137</sup>].

**Claim 53 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 54 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp<sup>101</sup>].

**Claim 55 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu<sup>137</sup>].

**Claim 56 (Currently amended)** The ~~mutein~~ method of claim 48, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 57 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~{Tyr<sup>101</sup>}~~ [Tyr<sup>101</sup>].

**Claim 58 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~{Tyr<sup>137</sup>}~~ [Tyr<sup>137</sup>].

**Claim 59 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~{Tyr<sup>89, 101</sup>}~~ [Tyr<sup>89, 101</sup>].

**Claim 60 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~{Tyr<sup>89, 137</sup>}~~ [Tyr<sup>89, 137</sup>].

**Claim 61 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~{Tyr<sup>101, 137</sup>}~~ [Tyr<sup>101, 137</sup>].

**Claim 62 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~{Tyr<sup>89, 101-137</sup>}~~ [Tyr<sup>89, 101, 137</sup>].

**Claim 63 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein is administered topically.

**Claim 64 (Currently amended)** The ~~mutein~~ method of claim 48, wherein the mutein is administered parenterally.

**Claim 65 (Previously presented)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has heart disease, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 66 (Previously presented)** The method of claim 65, wherein the patient has coronary artery disease.

**Claim 67 (Previously presented)** The method of claim 65, wherein the patient has myocardial infarction.

**Claim 68 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 69 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Asp101~~ [Asp<sup>101</sup>].

**Claim 70 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Leu137~~ [Leu<sup>137</sup>].

**Claim 71 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 72 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp<sup>101</sup>].

**Claim 73 (Currently amended)** The mutein of claim 65, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu<sup>137</sup>].

**Claim 74 (Currently amended)** The ~~mutein~~ method of claim 65, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 75 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr101]~~ [Tyr<sup>101</sup>].

**Claim 76 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr137]~~ [Tyr<sup>137</sup>].

**Claim 77 (Currently amended)** The ~~mutein~~ method of claim 65, which is human basic fibroblast growth factor ~~[Tyr89, 101]~~ [Tyr<sup>89, 101</sup>].

**Claim 78 (Currently amended)** The ~~mutein~~ method of claim 65, which is human basic fibroblast growth factor ~~[Tyr89, 137]~~ [Tyr<sup>89, 137</sup>].

**Claim 79 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr101, 137]~~ [Tyr<sup>101, 137</sup>].

**Claim 80 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr89, 101, 137]~~ [Tyr<sup>89, 101, 137</sup>].

**Claim 81 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein is administered topically.

**Claim 82 (Currently amended)** The ~~mutein~~ method of claim 65, wherein the mutein is administered parenterally.

**Claim 83 (Previously presented)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has peripheral vascular disease, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 84 (Currently amended)** The ~~mutein~~ method of claim 83, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 85 (Currently amended)** The ~~mutein~~ method of claim 83, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Asp<sup>101</sup>~~ [Asp<sup>101</sup>].

**Claim 86 (Currently amended)** The ~~mutein~~ method of claim 83, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Leu<sup>137</sup>~~ [Leu<sup>137</sup>].

**Claim 87 (Currently amended)** The ~~mutein~~ method of claim 83, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 88 (Currently amended)** The ~~mutein~~ method of claim 83, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Asp<sup>101</sup>~~ [Asp<sup>101</sup>].

**Claim 89 (Currently amended)** The ~~mutein~~ method of claim 83, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Leu<sup>137</sup>~~ [Leu<sup>137</sup>].

**Claim 90 (Currently amended)** The ~~mutein~~ method of claim 83, wherein a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 91 (Currently amended)** The ~~mutein~~ method of claim 83, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr<sup>101</sup>]~~ [Tyr<sup>101</sup>].

**Claim 92 (Currently amended)** The ~~muterin~~ method of claim 83, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr<sup>137</sup>]~~ [Tyr<sup>137</sup>].

**Claim 93 (Currently amended)** The ~~muterin~~ method of claim 83, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr<sup>89, 101</sup>]~~ [Tyr<sup>89, 101</sup>].

**Claim 94 (Currently amended)** The ~~muterin~~ method of claim 83, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr<sup>89, 137</sup>]~~ [Tyr<sup>89, 137</sup>].

**Claim 95 (Currently amended)** The ~~muterin~~ method of claim 83, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr<sup>101, 137</sup>]~~ [Tyr<sup>101, 137</sup>].

**Claim 96 (Currently amended)** The ~~muterin~~ method of claim 83, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr<sup>89, 101-137</sup>]~~ [Tyr<sup>89, 101, 137</sup>].

**Claim 97 (Currently amended)** The ~~muterin~~ method of claim 83, wherein the mutein is administered topically.

**Claim 98 (Currently amended)** The ~~muterin~~ method of claim 83, wherein the mutein is administered parenterally.

**Claim 99 (Previously presented)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has neural injury, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 100 (Currently amended)** The ~~muterin~~ method of claim 99, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~[[Glu<sup>89</sup>]]~~ [Glu<sup>89</sup>].

**Claim 101 (Currently amended)** The ~~muterin~~ method of claim 99, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Asp<sup>101</sup>~~ [Asp<sup>101</sup>].

**Claim 102 (Currently amended)** The ~~muterin~~ method of claim 99, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Leu<sup>137</sup>~~ [Leu<sup>137</sup>].

**Claim 103 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 104 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Asp<sup>101</sup>~~ [Asp<sup>101</sup>].

**Claim 105 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] comprises the substitution of a neutral amino acid for ~~Leu<sup>137</sup>~~ [Leu<sup>137</sup>].

**Claim 106 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 107 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr<sup>101</sup>]~~ [Tyr<sup>101</sup>].

**Claim 108 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr<sup>137</sup>]~~ [Tyr<sup>137</sup>].

**Claim 109 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr<sup>89, 101</sup>]~~ [Tyr<sup>89, 101</sup>].

**Claim 110 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr<sup>89, 137</sup>]~~ [Tyr<sup>89, 137</sup>].

**Claim 111 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr<sup>101, 137</sup>]~~ [Tyr<sup>101, 137</sup>].

**Claim 112 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein [[which]] is human basic fibroblast growth factor ~~[Tyr<sup>89, 101, 137</sup>]~~ [Tyr<sup>89, 101, 137</sup>].

**Claim 113 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein is administered topically.

**Claim 114 (Currently amended)** The ~~mutein~~ method of claim 99, wherein the mutein is administered parenterally.

**Claim 115 (Previously presented)** A method of stimulating fibroblast cell proliferation in a patient, wherein the patient has ischemia, the method comprising administering an effective amount of a mutein of human basic fibroblast growth factor or a biologically active peptide

thereof,

wherein the mutein of human basic fibroblast growth factor, or a biologically active peptide thereof, comprises the substitution of a neutral and/or hydrophobic amino acid for one or more of the following: (a) Glutamate 89; or (b) Aspartate 101; or (c) Leucine 137.

**Claim 116 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 117 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Asp101~~ [Asp<sup>101</sup>].

**Claim 118 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a hydrophobic amino acid for ~~Leu137~~ [Leu<sup>137</sup>].

**Claim 119 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~[[Glu89]]~~ [Glu<sup>89</sup>].

**Claim 120 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Asp101~~ [Asp<sup>101</sup>].

**Claim 121 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ comprises the substitution of a neutral amino acid for ~~Leu137~~ [Leu<sup>137</sup>].

**Claim 122 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ a neutral amino acid is defined as alanine and a hydrophobic amino acid is defined as tyrosine.

**Claim 123 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr101]~~ [Tyr<sup>101</sup>].

**Claim 124 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr137]~~ [Tyr<sup>137</sup>].

**Claim 125 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr89, 101]~~ [Tyr<sup>89, 101</sup>].

**Claim 126 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein ~~[[which]]~~ is human basic fibroblast growth factor ~~[Tyr89, 137]~~ [Tyr<sup>89, 137</sup>].

**Claim 127 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr<sup>101, 137</sup>~~] [Tyr<sup>101, 137</sup>].

**Claim 128 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein [[which]] is human basic fibroblast growth factor [~~Tyr<sup>89, 101-137</sup>~~] [Tyr<sup>89, 101, 137</sup>].

**Claim 129 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein is administered topically.

**Claim 130 (Currently amended)** The ~~mutein~~ method of claim 115, wherein the mutein is administered parenterally.